Xenomics to Present the Transrenal DNA Diagnostic Technology at General Meeting of the ASM
News May 29, 2006
Xenomics, Inc. has announced that Dr. Samuil Umansky, MD, Ph.D., Xenomics' Chief Science Officer, and Co-Founder, was invited to make a presentation regarding Transrenal DNA and its potential impact on global detection of Tuberculosis and other infectious diseases at the 106th General Meeting of the American Society for Microbiology in Orlando, Florida.
Dr. Umansky's presentation titled "Detection of Transrenal Mycobacterial DNA for Diagnosis and Monitoring of Tuberculosis" was one of the featured topics in "The Clinical Frontier" portion of the ASM program devoted to new technologies.
"We were pleased to be invited by the ASM to introduce this breakthrough DNA-based diagnostic technology," said Dr. David Tomei, CEO of Xenomics.
"We intend to utilize this platform to develop and commercialize a whole new generation of completely safe, non-invasive, and highly sensitive diagnostic testing products for the detection and monitoring of wide range of infectious diseases and other conditions."
Xenomics' proprietary Transrenal DNA diagnostic technology utilizes urine samples, rather than invasive blood or other samples.
Fragmented cellular DNA from throughout the body cross the kidney barrier and accumulate in the urine providing vital information about a wide range of conditions inside the body.
The Company believes this technology will foster fundamental improvements in safety, accuracy and functionality of testing in the field of molecular diagnostics, currently a US$1.5 billion segment of the healthcare industry.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.